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Abstract
Background: Chemotherapeutic drugs like Adriamycin (ADR) induces apoptosis or senescence in cancer cells but 
these cells often develop resistance and generate responses of short duration or complete failure. The methylxantine 
drug Pentoxifylline (PTX) used routinely in the clinics setting for circulatory diseases has been recently described to 
have antitumor properties. We evaluated whether pretreatment with PTX modifies apoptosis and senescence induced 
by ADR in cervix cancer cells.
Methods: HeLa (HPV 18+), SiHa (HPV 16+) cervix cancer cells and non-tumorigenic immortalized HaCaT cells (control) 
were treated with PTX, ADR or PTX + ADR. The cellular toxicity of PTX and survival fraction were determinated by WST-
1 and clonogenic assay respectively. Apoptosis, caspase activation and ADR efflux rate were measured by flow 
cytometry, senescence by microscopy. IκBα and DNA fragmentation were determinated by ELISA. Proapoptotic, 
antiapoptotic and senescence genes, as well as HPV-E6/E7 mRNA expression, were detected by time real RT-PCR. p53 
protein levels were assayed by Western blot.
Results: PTX is toxic (WST-1), affects survival (clonogenic assay) and induces apoptosis in cervix cancer cells. 
Additionally, the combination of this drug with ADR diminished the survival fraction and significantly increased 
apoptosis of HeLa and SiHa cervix cancer cells. Treatments were less effective in HaCaT cells. We found caspase 
participation in the induction of apoptosis by PTX, ADR or its combination. Surprisingly, in spite of the antitumor 
activity displayed by PTX, our results indicate that methylxantine, per se does not induce senescence; however it 
inhibits senescence induced by ADR and at the same time increases apoptosis. PTX elevates IκBα levels. Such 
sensitization is achieved through the up-regulation of proapoptotic factors such as caspase and bcl family gene 
expression. PTX and PTX + ADR also decrease E6 and E7 expression in SiHa cells, but not in HeLa cells. p53 was 
detected only in SiHa cells treated with ADR.
Conclusion: PTX is a good inducer of apoptosis but does not induce senescence. Furthermore, PTX reduced the ADR-
induced senescence and increased apoptosis in cervix cancer cells.
Background
Cervix cancer is the most frequently diagnosed female
cancer in developing countries and the second most fre-
quent cancer affecting women worldwide [1]. An esti-
mate of half a million new cases in 2008 were reported
[2]. The most important risk factor in this cancer is the
presence of human papilloma virus (HPV) infection.
High risk HPV types 16 and 18 are responsible for over
70% of cases of cervix cancer [3].
Cervix cancer, like other tumors shows two critical cel-
lular stages: apoptosis and senescence. The first one
occurs during normal or physiological conditions or by
stimuli such as chemotherapy and constitutes a common
pathway for cell replacement, tissue remodeling, dam-
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aged cell removal and elimination of cancer cells [4-6]. It
is a complex process which involves caspases participa-
tion, activation of proapoptotic genes, among other mol-
ecules. Apoptosis is defined by morphologic features
which include cell membrane blebbing, cell shrinkage,
chromatin condensation, and nucleosomal fragmentation
[7,8]. Cellular senescence, originally defined as a pheno-
type of arrested cells, after a certain number of cell divi-
sions. Now is considered a general biological program of
terminal growth arrest, and can be induced by the short-
ening of telomeres (growing old) or by injuries to DNA
which do not involve telomere shortening (accelerated
senescence) [9,10]. In this state, while they may remain
metabolically active, cells can not divide even if they are
stimulated by mitogens. They can be distinguished mor-
phologically by their enlarged and flattened cell shape
and increased granularity. This distinction is identifiable
with considerable specificity by detection of β-galactosi-
dase (SA-β-gal) by X-gal activity staining. Senescence
shows a dual role in cancer patients. Since this process
inhibits tumor cell proliferation it was considered to be a
protection mechanism. However, recent data suggest that
it also facilitates cancer progression [9-11].
Patients with advanced, persistent, or recurrent
squamous cell carcinoma are usually treated with cyto-
toxic chemotherapeutic agents such as Adriamycin
(ADR) which kills cancer cell mainly by apoptosis [9].
This drug can also induce senescence [12,13]; however,
tumor cells can develop resistance to chemotherapy and
generate responses of short duration or complete failure
[14]. Molecular basis of resistance to cancer therapy is
not well understood. It is considered that several factors
can play a role. Among these mechanisms, the transcrip-
tional nuclear factor-κB (NF-κB) is a key regulator of
genes involved in cellular proliferation, secretion of solu-
ble factors such as TNFα and up-regulation of antiapop-
totic genes [15-19].
Pentoxifylline (PTX), [1-(5-oxohexyl) 3, 7,-dimethylx-
anthine], is a nonspecific phosphodiesterase inhibitor
which has been already clinically and routinely used for
circulatory diseases for more than twenty years, and it is a
potent NF-κB and TNFα inhibitor. Recently, PTX has
been used to sensitize tumor cells to chemo- and radio-
therapy. In our experience, we have observed that lym-
phoma-bearing mice treated with PTX + ADR survived
more than one year after receiving only half of the stan-
dard therapeutically active ADR dose [20,21]. PTX also
sensitizes leukemic cells to perillyl alcohol-induced apop-
tosis [22] and also to prostatic tumor, HeLa and hepa-
toma cell line [23].
Cervix cancer is a public health problem and chemo-
therapy is not actually effective. Additionally, the effec-
tiveness of chemotherapy has been limited by its side
effects and/or the toxicity of these drugs in normal tis-
sues and normal cells. Thus, the use of pharmacological
agents that act by inhibiting resistance mechanisms or
sensitizing cancer cells to chemotherapy without increas-
ing side effects, are strongly desirable. We attempted to
study in vitro whether pretreatment with PTX modifies
apoptosis and senescence induced by ADR in cervix can-
cer cell lines.
Results
Cell viability of human cervix cancer cells after in vitro 
treatment with PTX or ADR either alone or in combination
We first evaluated cell sensitivity of HeLa, SiHa and
HaCaT cells to in vitro treatment with either PTX alone
or in combination with ADR, cell viability was deter-
mined in function of its metabolic activity by WST-1
assay. Table 1 shows the viability in comparison with
untreated control cells (100%). Cells treated with PTX,
had viability of 63.6 ± 2.1% in HeLa cells, 57.8 ± 1.0% in
SiHa cells and 74.1 ± 1.0% in HaCaT cells. When we used
ADR, the viability was 88.6 ± 3.0%, 70.1 ± 2.0%, and 95.0
± 7.6% in HeLa, SiHa and HaCaT cells, respectively. Addi-
tion of ADR to cells pre-incubated with PTX, signifi-
cantly decreased viability to 40.2 ± 1.0% for HeLa, 33.0 ±
1.2% for SiHa cells, but had little effect in HaCaT cells
(78.5 ± 1.1% viability). These results strongly suggest that
each drug individually decreases the viability of cervix
cancer cells, but in combination these effects are
increased.
Table 1: Viability of HeLa, SiHa or HaCaT cells after in vitro exposition to Pentoxifylline and Adriamycin
CELL LINE PERCENTAGE OF CELLULAR VIABILITY ± SD
GROUP HeLa SiHa HaCaT
PTX 8 mM 63.6 ± 2.1 57.8 ± 1.0 74.1 ± 1.0
ADR 1 μM 88.6 ± 3.0 70.1 ± 2.0 95.0 ± 7.6
PTX + ADR 40.2 ± 1.0 33.0 ± 1.2 78.5 ± 1.1
SD = standard deviation, Pentoxifylline = PTX, Adriamycin = ADR. Cultures cells were treated with PTX or ADR or their combination, 24 hours 
later the cells were harvested and cell viability was determined spectrophotometrically at 450 nm using WST-1 kit. The results are reported 
in percentage of cell viability as compared to untreated control groups respectively considered as 100% and the values represent the mean 
SD of three independent experiments.Bravo-Cuellar et al. Molecular Cancer 2010, 9:114
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Clonogenic assay in HeLa, SiHa and HaCaT cells after in 
vitro treatment with PTX or ADR either alone or in 
combination
The clonogenic assay is a proven method to study the tox-
icity of antitumor drugs. In Figure 1 we see when HeLa
cells are incubated with PTX or ADR or their combina-
tion at different doses. The response was dose specific,
showing little toxicity with low doses and incrementing
progressively with higher doses. In fact, all groups show a
linear regression comprise between r2 = 0.86 and 0.98, p <
0.05. The most important toxicity in HeLa cells was
reached with a dose of PTX (8 mM) + ADR (1 μM) which
presented a survival fraction of 0.01 ± 0.03. This value is
lower than the toxicities addition of each drug alone,
(survival fraction, PTX 0.28 ± 0.04 and ADR 0.16 ± 0.03).
For SiHa cells treated with PTX it was observed, than the
dose-response effect was not as clear as in the previous
experiment (r2 = 0.69, p <0.16). In contrast, in SiHa cells
exposed to ADR the dose-response effect was clear,
reaching a survival fraction with a lower dose of ADR
(0.25 μM) of 0.35 ± 0.03, and for the higher dose, the sur-
vival fraction decrease drastically 0.07 ± 0.02 (r2 = 0.94, p
< 0.03). Finally, SiHa cells were more sensitive to the drug
combination, since the most important effect was also
achieved detected when the cells were treated with PTX
+ ADR with the three different ADR doses. In the cloning
assay, no cells were observed because it reached a 100% of
toxicity. In the case of non-tumorigenic immortalized
HaCaT cells it was not observed a dose-response effect
and show a high degree of resistance in all cases (all
groups r2 = 0.38, p = 0.37). These results confirm our pre-
vious reports and suggest a probable potentializer effect
between PTX and ADR.
Figure 1 Clonogenic assay of HeLa, SiHa and HaCaT cells in vitro exposure for 6 hours to Pentoxifylline (PTX 8 mM) or Adriamycin (ADR 1 
μM) either alone or in combination. The cells were washed, trypsinized and suspended in drug-free medium and plated in 6-well plates. After 12 
days, the colonies were fixed stained and counted. The results are expressed as survival fraction and represent the mean. In all cases standard deviation 
was not greater than 0.03 of three independently experiments carrier out in triplicate. Statistical analysis Student "t" test.
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Pentoxifylline blocks Adriamycin efflux
It's likely that PTX may have other effects than sensitize
cancer cells to ADR such as reducing cellular ADR efflux.
Based on the fact that ADR is fluorescent, we investigated
the ADR efflux in HeLa, SiHa and HaCaT cells by flow
cytometry. In Figure 2 we observed the ADR fluorescence
in cervix cancer cells as well as in non-tumorigenic
immortalized cells. This observation was most important
in cancer cells; however the behavior was similar with
three cell lines studied. The results show that the ADR
concentration was higher in PTX + ADR group (MFI =
HeLa 324.3 ± 5.8, SiHa 107.9 ± 6.7 and HaCaT 75.5 ± 5.4)
than in the exclusively ADR group (MFI = HeLa 229.8 ±
6.3, SiHa 85.9 ± 4.7 and HaCaT 38.5 ± 5.4), p < 0.02. The
results suggest that PTX inhibits ADR efflux helping to
retain intracellular ADR.
Early apoptosis induced by PTX alone or in combination 
with ADR
Early apoptosis was evaluated by three different methods,
two of which were performed by flow cytometry:
Annexin V stain test (based on phosphatidylserine deter-
mination) and the detection of H2A.X histone (DNA
damage determination); the third method was an ELISA-
based photometric assay that measures cytoplasmic
DNA-histone nucleosome complexes generated during
apoptotic DNA fragmentation. Table 2 shows a homoge-
neous response for HeLa cells among the three methods.
In the untreated HeLa control group the percentage of
apoptosis was 3.7 ± 1.0%, 2.7 ± 0.2% and 10.0 ± 1.5% for
Annexin V, H2A.X histone and DNA-histone
nucleosome tests respectively. Surprisingly, the presence
of PTX in HeLa cell cultures induced apoptosis in an
important way with values that ranged between 30.5 ±
1.1%, 28.7 ± 1.0% and 30.3 ± 2.3% for the three tests
respectively (p  < 0.001 in all cases vs  corresponding
untreated control cells). The exclusive presence of ADR
in HeLa cell cultures also induced higher values of early
apoptosis than untreated control cells; 23.3 ± 2.1%, 28.6 ±
1.8% and 20.0 ± 1.7% for Annexin V, H2A.X and DNA-
histone nucleosome test respectively; p < 0.001 in com-
parison with the corresponding untreated control group.
When the HeLa cells were incubated with PTX + ADR
the most important values of early apoptosis were
reached, 38.4 ± 1.6%, 43.3 ± 2.5% and 31.0 ± 1.5% for the
three test respectively. These results are significantly
higher than in the cells treated either with exclusively
PTX or ADR alone (p < 0.001 with Annexin V and H2A.X
assays); however for the DNA-histone nucleosome test
the apoptosis was higher than the untreated control or
ADR treated cells (p < 0.001) but similar to the exclusively
PTX treated cells. The behavior of SiHa tumor cells was
similar to that observed in the previous experiment. In
the case of cell cultures treated with PTX + ADR, we
observed the most significant values of early apoptosis
41.5 ± 1.0% (Annexin V), 45.4 ± 2.6% (H2A.X) and 30.5 ±
1.5% (DNA-fragments) which represent an increment
over PTX-treated cells for each assay of 1.4, 2.4 and 1.5
times respectively (p < 0.005 in all cases vs corresponding
cells treated only with PTX or ADR). The experiment was
also carried out with immortalized non-tumorigenic cell
(HaCaT). In this experiment we observed that when early
apoptosis was measured by Annexin V staining, the most
significant result was seen in the cultures treated with
PTX + ADR (apoptosis = 23.1 ± 1.4%). A similar behavior
was observed in ELISA test. When considering these
results, it is important to stress that treatment with PTX
+ ADR induced a greater increase in apoptosis in HeLa
and SiHa cells when compared with either PTX or ADR
treatments as well as with HaCaT cells (p < 0.001).
Late apoptosis induced by PTX, ADR or their combination
To confirm the preceding observations, we studied late
apoptosis behavior in our experimental conditions by UV
light microscopy using ethidium bromide and acridine
orange. Figure 3 shows that the apoptotic indexes for
untreated HeLa, SiHa and HaCaT cells were 13.0 ± 1.9,
12.4 ± 0.8 and 7.1 ± 0.8 respectively. When the cells were
treated with PTX we observed apoptotic indexes of 43.4
± 4.4, 46.2 ± 2.4 and 12.8 ± 1.5 for HeLa, SiHa and HaCaT
cells respectively (p < 0.001 vs untreated cells). In HeLa,
SiHa and HaCaT cell cultures treated with ADR, were
observed 40.8 ± 1.8, 28.2 ± 0.9 and 10.2 ± 0.8 respectively
(p  < 0.001 comparing with untreated cells). When we
used PTX + ADR we observed an increase in the apop-
totic indexes of 62.4 ± 2.8, 50.0 ± 2.4 and 14.7 ± 0.5 in
HeLa, SiHa and HaCaT cells respectively (p < 0.001 vs
corresponding untreated cells). The whole apoptosis
observations strongly suggest that PTX is a good induc-
Figure 2 Effect of Pentoxifylline in Adriamycin efflux. ADR efflux 
was measured in HeLa, SiHa and HaCaT cells treated with PTX (8 mM), 
ADR (1 μM) or its combination and ADR efflux was determined by flow 
cytometry. The results represent the mean intensity fluorescence (MIF) 
± standard deviation of three independent experiments carrier out in 
triplicate. Statistical analysis ANOVA test. (*) p < 0.05 vs ADR.
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tor of apoptosis in cervix cancer cells and can also sensi-
tize cancer cells to ADR-induced apoptosis.
PTX and ADR induce caspase activation in HeLa and SiHa 
cells
In order to study the participation of caspase-dependent
apoptosis in our observations, we measured under the
s a m e  e x p e r i m e n t a l  c o n d i t i o n s  a s  d e s c r i b e d  a b o v e ,  t h e
amount of the M30 epitope present on caspase-cleaved
cytokeratin 18. Figure 4 shows that the percentage of
M30 positive cells was minimum in all three cell lines
without treatment with values between 1.9 ± 0.6% and 5.0
± 0.9%. In HeLa and SiHa cells significant caspase activity
was detected in all PTX and ADR treated cells; however,
the most important results were observed principally in
the PTX + ADR treated groups (p < 0.001 vs correspond-
ing untreated control, PTX or ADR groups). In opposi-
tion to this, in HaCaT cells we did not observe caspase
activity.
PTX reduces ADR-induced senescence in cervix cancer cells
Senescence is very relevant in Oncology and can be
induced by chemotherapy. For this reason, we deter-
mined whether PTX or ADR alone or in combination
induces senescence evaluating SA-β-Gal expression, a
well established senescence marker. Figure 5 show that
PTX in our experimental conditions does not induce
senescence in HeLa and SiHa cells. However, as expected
significant increases of senescence were observed in ADR
treated HeLa (senescence = 67.5 ± 11.5%) and SiHa cells
(senescence = 66.5 ± 11.0%), with values being 5.5 times
higher than untreated control or PTX treated cells (p <
0.001). We also observed that PTX greatly reduces the
senescence induced by ADR, since the percentage of
senescence found in PTX + ADR treated cultures of HeLa
cells (senescence = 26.6 ± 4.4%) and SiHa cells (senes-
cence = 24.4 ± 6.7%) represents a diminution of 2.5 and
2.7 folds in relation to the ADR treated group (p < 0.001
for both groups). PTX, ADR or their combination did not
induce senescence in HaCaT cells.
Table 2: Early apoptosis of HeLa, SiHa or HaCaT cells
HeLa
GROUP Annexin V H2A.X DNA-Fragmentation
(% mean ± SD) (% mean ± SD) (% mean ± SD)
CONTROL 3.7 ± 1.0 2.7 ± 0.2 10.0 ± 1.5
PTX 8 mM 30.5 ± 1.1 * 28.7 ± 1.0 * 30.3 ± 2.3 *
ADR 1 M 23.3 ± 2.1 * 28.6 ± 1.8 * 20.0 ± 1.7 *
PTX + ADR 38.4 ± 1.6 * 43.3 ± 2.5 * 31.0 ± 1.5 *
SiHa
GROUP Annexin V H2A.X DNA-Fragmentation
(% mean ± SD) (% mean ± SD) (% mean ± SD)
CONTROL 3.7 ± 1.0 2.5 ± 1.0 10.0 ± 1.5
PTX 8 mM 28.4 ± 2.1 * 19.0 ± 1.2 * 20.5 ± 1.8 *
ADR 1 M 27.0 ± 1.5 * 33.0 ± 3.0 * 17.5 ± 2.7 *
PTX + ADR 41.5 ± 1.0 * 45.4 ± 2.6 * 30.5 ± 1.5 *
HaCaT
GROUP Annexin V H2A.X DNA-Fragmentation
(% mean ± SD) (% mean ± SD) (% mean ± SD)
CONTROL 3.8 ± 0.2 3.3 ± 0.2 10.0 ± 1.5
PTX 8 mM 6.0 ± 0.7 6.2 ± 1.2 10.3 ± 1.8
ADR 1 M 15.5 ± 1.0 * 6.3 ± 0.9 10.2 ± 1.7
PTX + ADR 23.1 ± 1.4 * 5.5 ± 0.8 15.4 ± 1.5 *
Standard deviation = SD, Pentoxifylline = PTX, Adriamycin = ADR. Cell cultures were treated with PTX or ADR or their combination, 24 hours 
later the cells were harvested and apoptosis was determined by flow cytometry using Annexin V stained, H2A.X and DNA-histone 
nucleosome test by ELISA. The results represent the mean ± SD of three independent experiments carried out in triplicate. Statistical analysis 
Student "t" test. *p < 0.001 vs corresponding untreated control group.Bravo-Cuellar et al. Molecular Cancer 2010, 9:114
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PTX increases IκBα protein
As NF-κB induces cell proliferation its inhibition could be
part of the mechanism by which PTX and/or ADR works
as chemotherapeutic drug. IκBα plays a central role in
keeping NF-κB in the cytoplasm, and this blocks NF-κB
activation. For this reason, we performed a set of experi-
ments with ELISA test to determine whether PTX, ADR
or their combination modify levels of cytoplasmatic IκBα.
A s  F i g u r e  6  s h o w s ,  w h e n  H e L a  a n d  S i H a  c e l l s  w e r e
treated with PTX, we observed IκBα accumulation (p <
0.005 vs ADR and respectively untreated control groups).
In contrast, ADR treatment induced IκBα protein reduc-
tion which is more evident in SiHa and HaCaT cells (p <
0.005). Finally when the cervix cancer cells were treated
with PTX + ADR we observed an increment of IκBα pro-
tein compared with untreated control and exclusively
ADR treated cells (p < 0.005) and the contrary effect was
observed in HaCaT cells.
p53 protein expression and mRNA E6/E7 in HeLa and SiHa 
cells treated with PTX, ADR or PTX + ADR
It is well known that E6 and E7 oncogenes of HPV 16 and
18 are related to chemotherapy resistance and modulate
negatively the expression of genes such as p53. For this, in
our experimental conditions, we determined p53 protein
and mRNA levels. The results in Figure 7a allow us to
observe that p53 protein from HeLa cervical tumor cells,
as expected was not found in the control group and the
treated groups showed the same behavior. Results with
SiHa cells are similar to those found with HeLa, however
in this cell, ADR induces p53.
Oncoproteins E6 and E7 play a very important role
because they show close relation with p53 regulation. For
this reason were studied, in the same experimental condi-
tions, the mRNA expression in both cervical tumor cell
lines. In Figure 7b we can see that in HeLa cells, PTX
increased the expression of E6 mRNA (Δ% = 28). The
treatment with ADR induced a contrary effect in an
important fashion (Δ% = -84) and the experimental group
Figure 3 Late apoptosis in HeLa, SiHa and HaCaT cells after in vit-
ro exposure to Pentoxifylline (PTX) or Adriamycin (ADR) either 
alone or in combination. Cell cultures were treated with PTX (8 mM) 
or ADR (1 μM) or their combination (PTX + ADR), 24 hours later the cells 
were harvested and apoptosis was determined by UV light microscopy 
using ethidium bromide and acridine orange stains. The results repre-
sent the percentage of apoptosis ± standard deviation of three inde-
pendent experiments carrier out in triplicate. Statistical analysis 
Student "t" test. (*) p < 0.001 vs untreated cells (CT).
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Figure 4 Determination of caspases activity in HeLa, SiHa and 
HaCaT cells after in vitro treatment with Pentoxifylline (PTX) or 
Adriamycin (ADR) either alone or in combination. Cell cultures 
were treated with PTX (8 mM) or ADR (1 μM) or their combination (PTX 
+ ADR), 24 hours later the cells were harvested and caspase activity 
was determined measuring caspase-cleaved cytokeratin 18 neo-
epitope M30 by flow cytometry (M30 CytoDeath™ Biotin Kit). The re-
sults represent the percentage of caspase activity ± standard deviation 
of three independent experiments carrier out in triplicate. Statistical 
analysis Student "t" test. (*) p < 0.001 vs untreated control cells (CT). (•) 
p < 0.001 vs PTX or ADR groups.
M
3
0
 
 
C
y
t
o
D
E
A
T
H
 
%
HeLa                   SiHa                    HaCaT 
*
*
*
*
*
*


CT
PTX
ADR
PTX+ADR
Figure 5 Determination of SA-β-gal associated senescence of He-
La, SiHa and HaCaT cells after in vitro treatment with Pentoxifyl-
line (PTX) or Adriamycin (ADR) either alone or in combination. Cell 
cultures were treated with PTX (8 mM) or ADR (1 μM) or their combina-
tion (PTX + ADR), 24 hours later the cells were harvested and senes-
cence was determined by histochemistry using the BioVision 
senescence detection kit. The results represent the percentage of SA-
β-gal positive cells and represent the mean ± standard deviation of 
three independent experiments carrier out in triplicate. Statistical anal-
ysis Student "t" test. (*) p < 0.001 vs untreated control cells (CT). (•) p < 
0.001 vs ADR.
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treated with PTX + ADR increased E6 mRNA expression
in HeLa cells (HPV 18) with a Δ% = 33. In relationship to
E7 we observed practically a mirror behavior of E6 in all
treatments. In the same way we evaluated E6 and E7 in
SiHa cells (HPV 16). PTX did not modify mRNA expres-
sion of E6 (Δ% = 4) with ADR or PTX + ADR was strictly
similar between themselves and lower than the control
group (Δ% = -38 and -44 respectively). For E7 from HPV
16 we observed an important down regulation being
most important in PTX + ADR group (PTX Δ% = -52,
ADR Δ% = -43, PTX + ADR Δ% = -61).
mRNA expression of proapoptotic, antiapoptotic and 
senescence genes in cervix tumor cell lines after in vitro 
treatment with PTX alone or in combination with ADR
We determined the effects of PTX, ADR or PTX + ADR
on the expression of proapoptotic, antiapoptotic and
senescence genes in HeLa, SiHa and HaCaT cells. Real-
time PCR assay revealed that PTX treatment induced
modifications in the proapoptotic gene expression. Figure
8 shows a 0.3 to 3 fold up-regulation in bak, noxa, p21,
p53, diablo, caspase-3  and  caspase-9  genes mRNA
expression levels in HeLa cell treated with PTX or ADR.
In the same manner puma gene was up-regulated more
than 25 fold following treatment. In addition, the ADR
regulates others proapoptotic genes in HeLa cells. We
observed 0.3 to 3 fold up-regulation of bad and bax, and
senescence associated p16 gene mRNA expression levels
on HeLa cells. In the same way, when the HeLa cells were
t r e a t e d  w i t h  P T X  +  A D R,  m R N A  e x p r e s s i o n  l e v e l s  o f
bad, bax, bak, noxa, p16, p53 and diablo were 0.3 to 3
fold up-regulated, while in p21, caspase-3 and caspase-9
we found more than 3 fold up-regulation. However, we
observed over 40 fold up-regulation in puma gene in this
cell.
In SiHa cells treated with PTX, we found 0.3 to 3 fold
up-regulation in p16, p21, caspase-3, moreover caspase-9
was 4 fold up-regulated (Figure 8). When SiHa cells were
treated with ADR we observed 0.3 to 3 fold up-regulation
of  p21, diablo, caspase-3 and  caspase-9, p16 genes. In
SiHa cells treated with PTX + ADR, we observed 0.3 to 3
fold up-regulation of puma, diablo, caspase-3 and p16.
However the up-regulation was greater in caspase-9, p21
and noxa more than 3.7-fold increase (Figure 8). We also
found up-regulation in bad, bax, bak, noxa, puma, p21,
and diablo gene in HaCaT cells treated with PTX + ADR.
It was especially significant in puma and p21 genes being
above a 10 fold increase. On the contrary antiapoptotic
genes bcl-XL, mcl-1, and survivin were down-regulated or
not modified in practically all cellular lines by the differ-
ent treatments, with the exception of survivin  gene in
HeLa cells (1.6 fold increase) treated with PTX and mcl-1
in HeLa cells (0.8 fold increase) treated with PTX + ADR.
These data suggested the up-regulation in favour of genes
with proapoptotic activity principally in HeLa and SiHa
cancer cells treated with PTX + ADR.
Discussion
This work shows that PTX per se may induce apoptosis of
cervix cancer cell lines but does not induce senescence. In
the same manner, but no less important, PTX sensitizes
these cells to the induction of apoptosis by ADR and at
the same time reduces significantly the senescence
caused by this anthracycline.
Infections with high-risk HPV are the predominant
associated risk factors in the development of cervical can-
cer. In addition, proteins E6 and E7 expressed by HPV
contribute to resistance to treatments [23]. We used
HeLa and SiHa cells infected with HPV 18 and 16 respec-
tively to be closer to the most common HPV high risk
types observed in patients.
The studies of toxicity in cervix tumor cells, including
clonogenic assay show that PTX has antitumoral activity
by itself and the most important results are observed
when the cells are pretreated with PTX before ADR. All
these results strongly suggest that the combination of
PTX + ADR not only induced death in tumor cells, but
also reduced the number of cells with reproductive
capacity after treatment.
Early and late apoptosis were also induced more effi-
ciently by the combination of the drugs in the two cervix
cancer cell lines. Our results are in agreement with previ-
ous experiments and with the published data [24], sug-
gesting that the sensitizing effect of the PTX is due to a
Figure 6 Determination of IκBαin HeLa, SiHa and HaCaT cells af-
ter in vitro treatment with Pentoxifylline (PTX) or Adriamycin 
(ADR) either alone or in combination. Cell cultures were treated 
with PTX (8 mM) or ADR (1 μM) or PTX + ADR, 24 hours later the cells 
were harvested, protein was extracted and IκBα was determined by 
ELISA assays. The results show pg/mL of IκBα and represent the mean 
± standard deviation of three independent experiments carrier out in 
triplicate. Statistical analysis Student "t" test. (*) p < 0.005 vs untreated 
control cells (CT). (•) p < 0.005 vs ADR.
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general mechanism, present in different cell lines and not
in a particular one, even if the cells are infected with high
risk HPV.
To explain the differences in late apoptosis in HeLa and
SiHa culture treated with ADR, it is important consider
that late apoptosis it is not reversible and each system
could differ depending the genetic background of the
cells. For example HeLa cells have 50 integrated copies of
the HPV 18 whereas SiHa cells have only two copies of
the HPV 16 and its rate of replication is very different
[25].
The effect of PTX alone or in combination with ADR
has been related to caspase activation [21,26]. At this
point it is necessary to stress that in general our results
are in agreement with other experiments reported here,
so the higher or lower activity of caspases was correlated
with higher or lower percentage of apoptosis.
Senescence originally was defined as cell arrest growth
[10], and considered a novel tumor suppressive mecha-
nism [27]. However, the role of senescence in Oncology
has to be enlightened. It is true that the senescent cells
can not replicate itself, but it can stimulate the growth
and dissemination of other tumor cells by secretion of
different products like growth factors, cytokines and
metalloproteases. It has been reported that senescent
cells, induce an increment in the cell proliferation of pre-
cancerous cells [28,29]. To our knowledge, this is the first
report indicating that PTX alone can induce apoptosis
but does not induce a senescence cell state. In addition, it
is also very important to remark that PTX pretreatment
significantly reduces ADR-induced senescence and in
turn increases the apoptotic index in HeLa and SiHa can-
cer cells. Our observations support also the idea that
independently of the type of HPV virus that infects these
cells, they can undergo apoptosis which is preferable, to
cellular senescence.
These results can be explained biochemical and biolog-
ically by different facts: PTX is an effective inhibitor of
Figure 7 Western blot detection of p53 protein and mRNA of E6 and E7 in HeLa and SiHa cells at 24 and 3 hours respectively after in vitro 
treatment with Pentoxifylline (PTX 8 mM) or Adriamycin (ADR 1 μM) either alone or in combination. Effect of treatment on p53 protein, analysis 
by Western blot (a). Changes in the expression of E6 and E7 genes (b). Analysis of RT-PCR products was performed using LightCycler software. The 
data are expressed as fold increase or decrease of relative quantities, using ribosomal protein as a reference gene. The results represent the mean ± 
standard deviation of three independent experiments carrier out in triplicate.
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phosphodiesterase (PD) activity (mainly PD4), and has
also been reported to prevent the arrival of the NF-κB to
the cellular nucleus by inhibition of the phosphorylation
of serine 32 and 36 of the IκB complex in lymphoma and
the human monocyte cell line U937 [21,24]. In this sense,
w e  f i n d  t h a t  P T X  a l o n e  o r  i n  c o m b i n a t i o n  w i t h  A D R
causes an increment of IκBα in HeLa and SiHa cells. This
accumulation of IκBα induced by PTX could lead to a sig-
nificant retention and therefore less activation of NF-κB,
which in turn suppresses survival signals induced by this
factor.
Our results show that PTX decreases ADR efflux in
HeLa and SiHa cells and this increases the ADR cytotoxic
effect. It has been reported that PTX down-regulated
mdr1 gene expression and avoid ADR efflux, and in turn,
therefore decrease the resistance of L1210 leukemic cells
to ADR effects [30].
This methylxanthine arrests the cell cycle in the G2
phase, in which tumor cells are more sensitive to the toxic
effects of some chemotherapeutic agents and radiother-
apy [22,31]. ADR can induce reactive oxygen species
which are described as apoptosis or senescence inductors
[32]. PTX has been described as an antioxidant molecule
[33] and this may explain why PTX alone does not induce
senescence but impairs the senescence induced by ADR.
Using Real-Time PCR assay, we studied the mRNA
expression of genes related with induction of apoptosis,
caspases and senescence. In general we observed an up-
regulation of proapoptotic genes. The most important
up-regulation is observed in caspase-3 and caspase-9,
noxa, puma, and diablo  and down-regulation in anti-
apoptotic family genes in HeLa and SiHa cells treated
with PTX, ADR or both.
Figure 8 Comparison of relative quantity of mRNA of proapoptotic, antiapoptotic and senescence related genes in HeLa, SiHa and HaCaT 
cells after in vitro exposure to Pentoxifylline (PTX) or Adriamycin (ADR). Measurements were conducted using real-time RT-PCR. Cells cultures 
were treated with PTX (8 mM) or ADR (1 μM) or their combination (PTX + ADR) for 3 hours. Analysis of RT-PCR products was performed using Light-
Cycler software. The data are expressed as fold increase or decrease of relative quantities using ribosomal protein as a reference gene. Experiments 
were conducted in triplicates and repeated three times. In all cases standard deviation was not greater than 0.1.
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We observed up-regulation in p53 gene in HeLa cells
and in some groups of SiHa cells. The p53 protein was
not found except in SiHa cells treated exclusively with
ADR. This could indicate that apoptosis by PTX is p53-
independent and suggests the participation of other mol-
ecules such as caspase-3 and caspase-9 as observed in
this study. The up-regulation of the puma gene and p53
protein abrogation in these cells treated with PTX lets us
to suppose that multiples pathways may have been
involved to induce puma, such as endoplasmic reticulum
stress, FOXO3a and p73 [34].
We determined p53 protein levels in HeLa and SiHa
cells treated with PTX, ADR and PTX + ADR and its rela-
tionship with HPV E6 and E7 genes from HPV 18 and 16
respectively. Interestingly, ADR induced p53 protein sta-
bilization in SiHa cells and reduced mRNA levels of HPV
E6 and E7 in both cancer cells. In this sense, besides the
fact that ADR did not modify the mRNA levels of p53 in
SiHa cells, it impaired the degradation that could lead to
growth arrest or apoptosis. If survival factors are also
induced then growth arrest is favoured and the cell goes
in senescence. Premature senescence has been described
to be associated with increases in p53, p21, and p16 levels
[35,36].
When we measured the levels of mRNA expression of
HPV E6 and E7 in PTX + ADR treated cells we observe a
down-regulation in SiHa and an opposite effect in HeLa
cells. In this respect we can only speculate that the tran-
scriptional machinery used by HPV 16 and 18 is modu-
lated differentially by PTX.
It has been described that up-regulation of p16 is asso-
ciated with senescence [35,36]. We detected up-regula-
tion of p16 gene when SiHa and HeLa cells were treated
with ADR and this is in agreement with the senescence
observed in these cells and contrarily when the cells were
treated with PTX.
Conclusion
Our observations show antitumor activity of PTX. This
molecule induces apoptosis in a p53 independent manner
and decreases the senescence induced by ADR. Impor-
tantly, PTX increases the sensitivity of cancer cells to the
toxic effects of ADR by caspase participation and regula-
tion of caspase -3,  caspase-9,  puma,  noxa, and diablo
genes.
Methods
Cell lines
HeLa (HPV 18+) and SiHa (HPV 16+) cervical cancer cell
lines and the spontaneously immortalized human epithe-
lial cell line HaCaT (used as non-tumorigenic control
cells) were kindly provided by Dr. Boukamp (DKFZ-
Heidelberg, Germany). All the cell lines were maintained
in vitro and propagated in Dulbecco's modified Eagle's
culture medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum, 1× L-glutamine (2 mM
final concentration) and antibiotics (penicillin/strepto-
mycin), (this medium will be referred to as DMEM- S),
and incubated at 37°C in an humidified atmosphere con-
taining 95% air and 5% CO2. All the previously mentioned
products were obtained from GIBCO™ Invitrogen Corpo-
ration (Carlsbad, CA, USA).
Drugs and experimental conditions
Adriamycin (ADR) was obtained from Lemery Laborato-
ries, México, and stocked at 4°C less than 4 days and
adjusted to desirable concentration with DMEM culture
medium immediately before utilization. Pentoxifylline
(PTX) (Sigma, Saint Louis MO, USA) dissolved in sterile
saline solution 0.15 M, at a concentration of 0.2 M and
kept at 4°C less than 4 days.
Cell culture and in vitro treatments
HeLa, SiHa and HaCaT cells suspended in DMEM-S at
concentrations of 1.5 × 106 or 2 × 106/8 mL in exponential
phase were seeded in p100 Petri dishes for flow cytome-
try assays, senescence and Western blot studies. For sur-
vival test and for apoptosis determined by ELISA, the
cells were cultured in 96-well plates at a concentration of
3 × 105 cells/well/200 μL (final volume). For clonogenic
assays the cells were seeded at densities of 1 × 104 cells/2
mL in 6-well plates. In all cases the cells were cultured
overnight at 37°C in a humidified atmosphere containing
5% of CO2 and 95% air. The medium was then replaced
with DMEM-S. Then the cells were either treated with
PTX 8 mM, or ADR 1 μM or PTX + ADR (final concen-
trations). The cells were incubated with PTX 1 hour
before ADR addition and 24 hours later the culture cells
were harvested. In the cases for genes expression study
the cells were incubated with the drugs for only 3 hours.
Cell survival
Cells survival was determined by the cleavage of tetrazo-
lium salt WST-1 into formazan by cellular mitochondrial
dehydrogenase enzyme. 24 hours after each treatment
the cell were incubated as above indicated with 10 μL/
well of WST-1/ECS solution (BioVision Research, Moun-
tain View, CA, USA) and incubated for 3 hours in the
same conditions. The absorbance (450 nm) of the treated
and untreated samples was determined on a microtiter
plate reader (Synergy™ HT Multi-Mode Microplate
Reader. Biotek Winooski, VT, USA). Data are reported in
percentage of cell survival as com pared to respectively
untreated control group considering as 100%.Bravo-Cuellar et al. Molecular Cancer 2010, 9:114
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Clonogenic Survival Assays
Cells were assayed for the cytotoxic effects of PTX or
ADR or PTX + ADR after cell survival according to the
established methods of performing the clonogenic
assay [37]. Subconfluent cultures were exposed to
drugs for 6 hours. Then the cells were washed with
PBS preheated to 37°C, trypsinized and plated in 6-
well plates (100 cells/wells). After 12 days of incuba-
tion in complete culture medium, the colonies were
stained with crystal violet after fixation with formalde-
hyde and counted manually. In each case the results
are expressed as survival fraction which was obtained
by dividing the number of colonies after the treatment
by the number of cells seeding and the results multiply
by the plate efficiency (PE). PE = (N°. of colonies
formed/N° of cells seeded) ×100.
Adriamycin efflux assay
HeLa, SiHa and HaCaT cells were incubated with ADR
for 1 hour in DMEM-S at 37°C. For ADR efflux measure-
ment, the cells were washed with DMEM-S and treated or
untreated with PTX for 2 hours at 37°C. The cells were
washed, trypsinized and collected in drug-free medium.
A D R  f l u o r e s c e n c e  w a s  d e t e r m i n e d  i n  F A C S A r i a  c e l l
sorter (BD, Bioscience, San Jose, CA, USA). For tests at
least 20,000 events were analyzed for each sample. Data
were processed with the FACSDiva software package
(BD). The results are reported as the mean intensity fluo-
rescence.
Apoptosis and caspase activity detection methods
Cellular detection of Annexin V, H2A.X phosphorylation
and M30 caspase activity were determined by flow
cytometry using the fluorescein isothiocyanate conju-
gated monoclonal Annexin V-FITC apoptosis Kit
(Annexin-V-Fluos; Roche, Mannheim, Germany), H2A.X
phosphorylation assay kit (H2A.X Phosphorylation Assay
Kit, Millipore Temecula, CA, USA) and M30 Cyto-
DEATH™ Biotin antibody (Roche Mannheim, Germany)
respectively according to the manufacturer's instructions.
For the three tests at least 20,000 events were analysed for
each sample in an EPICS XL-MCL™ Flow Cytometer
Beckman Coulter model (Fullerton, CA, USA). Data were
processed with the System II software package (Beckman
Coulter).
Apoptosis Detection by ELISA
In normal untreated and treated cell cultures we determi-
nated cytoplasmic histone-associated-DNA-fragments
(mono- and oligonucleosomes) spectrophotometrically
(420 nm) using Cell Death Detection ElisaPLUS (Roche
Mannheim, Germany) according the manufacturer's
instruction [38]. The enrichment of mono- and oligonu-
cleosomes released into the cytoplasm was calculated:
experimental absorbance/corresponding control absor-
bance. The results are expressed as the percentage of
DNA fragmentation.
Acridine orange/ethidium bromide staining to detect late 
apoptosis by UV-microscopy
Briefly the cells were stained with ethidium bromide
(Sigma Saint Louis MO, USA) and acridine orange
(Sigma, Saint Louis MO, USA) (100 μg/mL each). Two
hundred cells were counted and number of each of the
following 4 cellular states recorded: i) live cells with nor-
mal nuclei (LN), bright green chromatin and organized
structure; ii) apoptotic cells (A) with highly condensed or
fragmented bright green-yellow chromatin; iii) dead cells
with normal nuclei (DN), bright red chromatin and orga-
nized structure and iv) dead cells with apoptotic nuclei
(DA) and bright orange chromatin, which were highly
condensed and fragmented. Apoptotic index (AI): A +
DA/LN +A +DN +DA × 100.
β-galactosidase associated senescence
According to the manufacturer's instructions senescence
was determined by histochemical in treated and
untreated control cells by Senescence Detection Kit (Bio-
Vision Mountain View, CA, USA) which detects β-galac-
tosidase activity (SA-β-gal) present in senescence cells.
We counted 300 cells of six microscopic fields to deter-
mine the percentage of SA-β-gal stained positive cells
identified by an intense blue stain in the membrane.
Protein extraction for IκBα ELISA and p53 western blot 
assay
1-2 × 106 cells were seeded in p100 culture Petri-dishes
and treated next day with PTX, ADR and PTX + ADR for
24 hours. After treatment, cells were harvested by scrap-
ing and lysed with RIPA buffer (0.5% deoxycholate, 0.5%
NP-40, 0.5% SDS, 50 mM Tris pH 7.4 and 100 mM NaCl)
containing protein inhibitors. Following sonication (15
pulses, 50% amp), protein extracts were obtained after 30
min incubation at 4°C and 5 min centrifugation at 14 000
rpm/4°C. Protein concentrations were determined using
BioRad Dc Protein Kit.
IκBα detection
The levels of IκBα protein was determined in HeLa, SiHa
and HaCaT treated and untreated control cells using a
commercial ELISA kit at 450 nm (Invitrogen), according
to the manufacturer's instructions. The results are
expressed in pg/mL.
p53 Western blot analyses
Total cell protein (50 μg) was subjected to electrophoresis
using a 12% sodium dodecyl sulfate polyacrylamide gel.
Subsequently, proteins were transferred to Immobilon-PBravo-Cuellar et al. Molecular Cancer 2010, 9:114
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PVDF membranes (Millipore) and incubated with 1×
western blocking reagent (Roche) during 1 hour for non-
specific binding. Immunodetection of p53 was performed
using anti-p53 (DO-1, dilution 1:750, Santa Cruz biotech-
nology, Inc.) at room temperature for 2 hours. After incu-
bation with a horseradish peroxidase-conjugated
secondary antibody, immunoreactive proteins were visu-
alized by western blotting luminol reagent in chemilumi-
niscence films and resolved on BioMax film (Kodak)
according to the manufacture's specifications. Control β-
actin antibody.
Quantitative real time PCR
Total RNA from both cells was obtained after 3 hours of
incubation using the PureLink™ Micro-to-Midi total RNA
purification system (Invitrogen Corporation, Carlsbad,
CA, USA). First-strand cDNA was synthesized from 5 μg
of total RNA using Superscript™ III First-Strand Synthesis
Supermix (Invitrogen Corporation, Carlsbad, CA, USA).
Real Time PCR was performed using a LightCycler® 2.0
apparatus (Roche Applied Science, Mannheim, Germany)
and LightCycler-FastStart DNA MasterPLUS SYBR Green I
(Roche Applied Science, Mannheim, Germany). Analysis
of PCR products was performed using LightCycler® soft-
ware (Roche Applied Science, Mannheim, Germany). The
data are expressed as relative quantities using a reference
gene (Protein Ribosomal). Each sample was processed in
triplicate to verify the specificity of the amplification
reaction. Oligonucleotides (Invitrogen Corporation,
Carlsbad, CA, USA) used to amplify human bad, bax,
bak, noxa, puma, diablo, caspase-3, caspase-9, mcl-1, sur-
vivin, bcl-XL, p21, p53,  p16, E6 and E7 (HPV16 and
HPV18) and Ribosomal Protein are shown in Table 3. Oli-
gonucleotides were designed using the Oligo v.6 software.
Gene sequences were obtained from the GenBank Nucle-
otide Database of the National Center for Biotechnology
Information http://www.ncbi.nlm.nih.gov.
Statistical analysis
Results of each experiment represent mean ± standard
deviation (SD) of 3 independent experiments carried out
in triplicate. Differences between groups were deter-
mined by Student "t" test and ANOVA. Significant results
were considered with p  < 0.05. For the comparison of
gene expression, it was only considered positive or nega-
tive differences ≥30% in relationship to reference values.
In some cases was calculated the Δ% that represent the
percent of increment or diminution in relationship to
comparative group.
Table 3: Primer pairs used for real-time quantitative PCR
Gene Primer pair sequences
bad 5'CTC CGG AGG ATG AGT GAC GAGT 3'
5'ACT TCC GCC CAT ATT CAA GAT 3'
bak 5'CGC TTC GTG GTC GAC TTC AT 3'
5'AGA AGG CAA AGA CTT CGC TTA 3'
bax 5'TTT GCT TCA GGG TTT CAT CC 3'
5'CAG TTG AAG TTG CCG TCA GA 3'
noxa 5'GAG ATG CCT GGG AAG AAG G 3'
5'TCC TGA GCA GAA GAG TTT GGA 3'
puma 5' GAT GGC GGA CGA CCT CAA C 3'
5'TGG GAG TCC AGT ATG CTA CAT GGT 3'
survivin 5'TGA GCT GCA GGT TCC TTA TCT G 3'
5'GAA TGG CTT TGT GCT TAG TTT T 3'
diablo 5'TGA CTT CAA AAC ACC AAG AGT A 3'
5'TTT CTG ACG GAG CTC TTC TA 3'
p21 5'CGA CTT TGT CAC CGA GAC AC 3'
5'CGT TTT CGA CCC TGA GAG T 3'
p53 5'CTG AGG TTG GCT CTG ACT GTA CCA CCA TCC 3'
5'CTC ATT CAG CTC TCG GAA CAT CTC GAA GCG 3'
p16 5'CAG TAA CCA TGC CCG CAT AGA T 3'
5'TGA AAA GGC AGA AGC GGT GT 3'
mcl-1 5'CAC GAG ACG GTC TTC CAA GGA TGC T 3'
5'CTA GGT TGC TAG GGT GCA ACT CTA GGA 3'
bcl-XL 5'GCA GGC GAC GAG TTT GAA CT 3'
5'GTG TCT GGT CAT TTC CGA CTG A 3'
Caspase-3 5'ATA CTC CAC AGC ACC TGG TTA T 3'
5'AAT GAG AGG GAA ATA CAG TAC CAA 3'
Caspase-9 5'GTA CGT TGA GAC CCT GGA CGA C 3'
5'GCT GCT AAG AGC CTG TCT GTC ACT 3'
E6 (HPV 18) 5'GCG ACC CTA CAA GCT ACC TGA T 3'
5'GCA CCG CAG GCA CCT TAT TA 3'
E7 (HPV 18) 5'TGT CAC GAG CAA TTA AGC GAC T 3'
5'CAC ACAAAG GAC AGG GTG TTC A 3'
E6 (HPV 16) 5'CAG AGC TGC AAA CAA CTA TAC 3'
5'AGT GGC TTT TGA CAG TTA ATA C3
E7 (HPV 16) 5'GAC AAG CAG AAC CGG ACA G 3'
5'ATT CCT AGT GTG CCC ATT AAC A 3'
ribosomal 5'GCA TTG ACA ACA GGG TTC GTA G 3'
protein 5'ATT TAA ACA GAA AAC GTG CAC A 3'
Oligonucleotides were designed using the Oligo v.6 software. 
Gene sequences were obtained from the GenBank Nucleotide 
Database of the National Center for Biotechnology Information 
http://www.ncbi.nlm.nih.gov.Bravo-Cuellar et al. Molecular Cancer 2010, 9:114
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